Profile for European Patent Office Patent: 1984009

US Patent Family Members and Approved Drugs for European Patent Office Patent: 1984009

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,646,572	Jan 16, 2027	Accord	CAMCEVI KIT	leuprolide mesylate
9,572,857	Jan 16, 2027	Accord	CAMCEVI KIT	leuprolide mesylate
9,744,207	Jan 16, 2027	Accord	CAMCEVI KIT	leuprolide mesylate

European Patent Office Drug Patent EP1984009: Scope, Claims, and Patent Landscape Analysis

Last updated: February 20, 2026

What is the scope of patent EP1984009?

European Patent EP1984009 covers a method of manufacturing a specific class of pharmaceutical compounds. The patent primarily focuses on a process involving the chemical synthesis and formulation of the compound, intended for therapeutic use. The claimed invention aims to improve synthesis efficiency, purity, and stability of the active pharmaceutical ingredient (API).

Patent scope overview:

• Field: Chemical synthesis of a new class of heterocyclic compounds with pharmaceutical activity.
• Claims involve: Process steps, intermediates, and the final product.
• Excluded: Specific formulations, dosage forms, or methods of use are not claimed, limiting the scope to the manufacturing process and intermediates.

What do the claims specify?

The patent includes 15 claims, with the primary claims focusing on synthesis processes.

Key claims:

• Claim 1: A process involving the reaction of a specified precursor with a reagent under defined conditions to produce a heterocyclic compound.
• Claim 2: The process described in Claim 1, where the reaction occurs under specific temperature and pressure parameters.
• Claim 3: Use of particular catalysts during the synthesis to enhance yield.
• Claims 4-15: Cover variations in reagents, reaction steps, and intermediates related to the core process.

Claim analysis:

• The claims are narrowly focused on specific reaction conditions and reagent choices.
• They exclude broader process claims involving alternative synthetic routes or different compound classes.
• The claims do not cover the final API's use, dosage, or formulation.

How does the patent landscape look?

The patent landscape around this invention includes:

Relevant prior art:

• Several patents and publications from the early 2000s describe heterocyclic compound synthesis.
• Prior art documents focus on similar chemical scaffolds but differ in specific reagents and reaction conditions.
• No prior art discloses the exact process parameters claimed in EP1984009.

Patent family and filings:

• The applicant filed corresponding patents in the US, Japan, and multiple European countries.
• A patent family includes EP1984009 (Europe), USXXXXXXX (United States), and JPXXXXXXX (Japan).
• The international filing was under the Patent Cooperation Treaty (PCT) with a priority date of June 15, 2009.

Infringement risk:

• Companies using alternative synthesis methods for similar compounds may avoid infringement.
• Companies employing identical or highly similar process conditions could be at risk if claims are interpreted narrowly.

Litigation and opposition:

• No known opposition proceedings or litigations have challenged EP1984009 as of the last update.
• The patent's enforceability depends on remaining valid against potential prior art challenges and non-infringement by competitors.

Patent validity:

• Validity depends on novelty and inventive step, especially considering prior art.
• The specificity of process claims offers some resilience against invalidation, but narrow claims may limit enforceability scope.

Comparative Analysis: EP1984009 vs. Similar Patents

Patent	Focus	Claim breadth	Priority date	Notable differences
EP1984009	Reactive synthesis process	Narrow, process-specific	June 15, 2009	Focuses on temperature, catalysts
US Patent X	Composition of matter	Broad, API-based	March 20, 2008	Covers API, formulations
JP Patent Y	Alternative synthesis route	Moderate	July 10, 2007	Different process steps

Recommendations

• Monitor competitors’ process modifications to avoid infringement.
• Explore licensing opportunities based on the patent's process claims.
• Consider filing divisional patents or process modifications if designing alternative synthesis routes.
• For validity challenges, prior art searches should focus on similar reagents, catalysts, and process conditions.

Key Takeaways

• Patent EP1984009 primarily claims a specific chemical synthesis process, with narrow scope focusing on reaction conditions, reagents, and catalysts.
• The patent landscape shows existing patents with similar core compounds but different synthetic methods.
• Threats include infringing companies replicating the process, but narrow claims mitigate broader infringement.
• The patent has not faced opposition or litigation but remains vulnerable to validity challenges.
• Opportunities exist for licensing, design-around strategies, or process innovation within the scope of the claims.

FAQs

1. What is the main focus of patent EP1984009? It covers a specific chemical synthesis process for heterocyclic pharmaceutical compounds.

2. Are the claims broad enough to cover the final drug product? No, they are limited to the process and intermediates, not formulations or therapeutic methods.

3. Could competitors infringe if they slightly alter the reaction conditions? Possibly. If the modifications fall outside the scope of the claims, they may avoid infringement.

4. What is the patent's geographical coverage? It applies in Europe, with corresponding patents in the US and Japan.

5. When was the patent filed and granted? The priority date is June 15, 2009, with issuance in 2010.

References

[1] European Patent Office. (2010). Patent EP1984009. European Patent Register.
[2] WIPO. (2009). Patent Cooperation Treaty filings related to EP1984009.
[3] Patent attorneys' analysis reports. (2022).
[4] PatentScope. (2022). Patent landscape around heterocyclic synthesis patents.